<DOC>
	<DOC>NCT00315003</DOC>
	<brief_summary>This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2- treatmentgroup study in children (age range: ≥6 months and &lt;72 months [&lt; 6 years of age]) with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and 250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin will also be dispensed to provide blinding for the different treatment regimens.Assessments and reporting of safety will be carried out at all visits.</brief_summary>
	<brief_title>TELI COM - Telithromycin in Children With Otitis Media</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Suppuration</mesh_term>
	<mesh_term>Otitis Media, Suppurative</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Subjects meeting all of the following criteria will be considered for enrollment into the study: Subjects ≥6 months and &lt;72 months (&lt; 6 years) of age; Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs; The presence of MEF on otoscopy indicated by a bulging tympanic membrane; Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep; At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability; Caregiverreported AOM symptoms sufficient for entry according to protocol criteria. Caregiverreported AOM symptoms diary Tympanometry exhibiting: Type B curve or positive pressure peak curves. Subjects presenting with any of the following will not be included in the study: Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 23 days. Otorrhea or tympanostomy tube present in the ear to be evaluated; Otitis externa; Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with &lt;25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection; Known congenital long QT syndrome; Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia, bradycardia (&lt;50 bpm); Myasthenia gravis; Known impaired renal function, as shown by creatinine clearance ≤25 mL/min; History of hypersensitivity or intolerance to macrolides or azithromycin; Previous enrollment in this study or previous treatment with telithromycin; Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Otitis Media</keyword>
	<keyword>Suppurative</keyword>
	<keyword>Purulent</keyword>
	<keyword>Ketolide</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Telithromycin</keyword>
	<keyword>Controlled Clinical Trials</keyword>
</DOC>